HMGB-1

Acronym

Definition

HMGB-1

High Mobility Group Box Chromosomal Protein 1

References in periodicals archive	?		Acronyms browser	?		Full browser	?
The Company's current research and development portfolio includes HMGB-1, a pro-inflammatory substance identified as a mediator of TNF-associated tissue damage; development of small molecule and vagal nerve stimulation approaches to treat inflammation; and CTI-01, a proprietary anti-inflammatory drug candidate currently in Phase I clinical trials. Critical Therapeutics In-Licenses Asthma Drug Program from Abbott ... by Business Wire These products include its lead drug (an improved, controlled-release formulation of a drug currently approved for the treatment and prophylaxis of asthma), a cytoprotective drug to reduce trauma-related vascular and organ damage currently in Phase I clinical trials, and biologic products targeting HMGB-1, a novel pro-inflammatory cytokine to treat severe inflammatory diseases in partnership with MedImmune. Critical Therapeutics Raises $56 Million in Series B Financing by Business Wire The Company's current research and development portfolio includes the following therapeutic targets: HMGB-1, a pro-inflammatory substance identified as a mediator of TNF-associated tissue damage; development of small molecule and vagal nerve stimulation approaches to treat inflammation; and CTI-01, a proprietary anti-inflammatory drug candidate currently in Phase I clinical trials. Critical Therapeutics Announces Issuance of U.S. Patent for Novel ... by Business Wire	HMFG1 HMFGM HMFI HMFIC HMFL HMFP HMFS HMFT HMFW HMFWIC HMFWS HMG HMG-1 HMG-14 HMG-17 HMG-CoA hMG-hCG HMG-I HMG-T HMG1 HMG1/2 HMG12 HMG2 HMGA HMGB HMGB-1 HMGB1 HMGC HMGCC HMGCL HMGCR HMGCS HMGCS2 HMGD HMGEL HMGF HMGI HMGI/Y HMGIC HMGN HMGP HMGPA HMGR HMGS HMGT HMH HMHA HMHB HMHC HMHD HMHEC	HMG CoA HMG CoA HMG CoA reductase HMG CoA reductase HMG CoA reductase inhibitor HMG-1 HMG-14 HMG-17 HMG-CoA HMG-CoA lyase HMG-CoA reductase HMG-CoA reductase HMG-CoA reductase i HMG-CoA reductase i HMG-CoA reductase i HMG-CoA reductase i HMG-CoA reductase inhibitor HMG-CoA reductase inhibitor HMG-CoA reductase inhibitors HMG-CoA reductase inhibitors HMG-CoA synthase deficiency hMG-hCG HMG-I HMG-T HMG1 HMG1/2 HMG12 HMG2 HMGA HMGB HMGB-1 HMGB1 HMGC HMGCC HMGCL HMGCoA reductase HMGCoA reductase HMGCR HMGCS HMGCS2 HMGD HMGEL HMGF HMGI HMGI/Y HMGIC HMGN HMGP HMGPA HMGR HMGS HMGT HMH HMHA Hmhb HMHC

References in periodicals archive

Acronyms browser

Full browser

The Company's current research and development portfolio includes HMGB-1, a pro-inflammatory substance identified as a mediator of TNF-associated tissue damage; development of small molecule and vagal nerve stimulation approaches to treat inflammation; and CTI-01, a proprietary anti-inflammatory drug candidate currently in Phase I clinical trials.

Critical Therapeutics In-Licenses Asthma Drug Program from Abbott ... by Business Wire

These products include its lead drug (an improved, controlled-release formulation of a drug currently approved for the treatment and prophylaxis of asthma), a cytoprotective drug to reduce trauma-related vascular and organ damage currently in Phase I clinical trials, and biologic products targeting HMGB-1, a novel pro-inflammatory cytokine to treat severe inflammatory diseases in partnership with MedImmune.

Critical Therapeutics Raises $56 Million in Series B Financing by Business Wire

The Company's current research and development portfolio includes the following therapeutic targets: HMGB-1, a pro-inflammatory substance identified as a mediator of TNF-associated tissue damage; development of small molecule and vagal nerve stimulation approaches to treat inflammation; and CTI-01, a proprietary anti-inflammatory drug candidate currently in Phase I clinical trials.

Critical Therapeutics Announces Issuance of U.S. Patent for Novel ... by Business Wire